Literature DB >> 33681191

Cathepsin D Variants Associated With Neurodegenerative Diseases Show Dysregulated Functionality and Modified α-Synuclein Degradation Properties.

Josina Bunk1, Susy Prieto Huarcaya1,2, Alice Drobny1,2, Jan Philipp Dobert1,2, Lina Walther1, Stefan Rose-John1, Philipp Arnold3,4, Friederike Zunke1,2.   

Abstract

Cathepsin D (CTSD) is a lysosomal protease important for the degradation of various substrates, including disease-associated proteins like α-synuclein (a-syn), amyloid precursor protein (APP) and tau, all of which tend to aggregate if not efficiently degraded. Hence, it is not surprising that genetic variants within the CTSD gene have been linked to neurodegenerative diseases, like Parkinson's and Alzheimer's disease (PD, AD), as well as the lysosomal storage disorder neuronal ceroid lipofuscinosis type-10 (NCL10). Although recent studies have shown the molecular dependence of substrate degradation via CTSD within autophagic pathways, only little is known about the precise role of lysosomal CTSD function in disease development. We here performed biochemical, cellular and structural analyses of eleven disease-causing CTSD point mutations found in genomic sequencing data of patients to understand their role in neurodegeneration. These CTSD variants were analyzed for cellular localization, maturation and enzymatic activity in overexpression analyses. Moreover, for PD-associated mutants, intracellular degradation of a-syn was monitored. In summary, our results suggest that NCL10-associated CTSD variants are significantly impaired in lysosomal maturation and enzymatic activity, whereas the AD- and PD-associated variants seemed rather unaffected, indicating normal maturation, and lysosomal presence. Interestingly, a PD-associated CTSD variant (A239V) exhibited increased enzymatic activity accompanied by enhanced a-syn degradation. By structural analyses of this mutant utilizing molecular dynamics simulation (MDS), we identified a structural change within a loop adjacent to the catalytic center leading to a higher flexibility and potentially accelerated substrate exchange rates. Our data sheds light onto the role of CTSD in disease development and helps to understand the structural regulation of enzymatic function, which could be utilized for targeted CTSD activation. Because of the degradative function of CTSD, this enzyme is especially interesting for therapeutic strategies tackling protein aggregates in neurodegenerative disorders.
Copyright © 2021 Bunk, Prieto Huarcaya, Drobny, Dobert, Walther, Rose-John, Arnold and Zunke.

Entities:  

Keywords:  Parkinson’s disease; alpha-synuclein; cathepsin D; lysosomal degradation; lysosomes; molecular dynamics simulation; neuronal ceroid lipofuscinoses

Year:  2021        PMID: 33681191      PMCID: PMC7928348          DOI: 10.3389/fcell.2021.581805

Source DB:  PubMed          Journal:  Front Cell Dev Biol        ISSN: 2296-634X


  64 in total

1.  UCSF Chimera--a visualization system for exploratory research and analysis.

Authors:  Eric F Pettersen; Thomas D Goddard; Conrad C Huang; Gregory S Couch; Daniel M Greenblatt; Elaine C Meng; Thomas E Ferrin
Journal:  J Comput Chem       Date:  2004-10       Impact factor: 3.376

2.  Cathepsin D deficiency induces lysosomal storage with ceroid lipofuscin in mouse CNS neurons.

Authors:  M Koike; H Nakanishi; P Saftig; J Ezaki; K Isahara; Y Ohsawa; W Schulz-Schaeffer; T Watanabe; S Waguri; S Kametaka; M Shibata; K Yamamoto; E Kominami; C Peters; K von Figura; Y Uchiyama
Journal:  J Neurosci       Date:  2000-09-15       Impact factor: 6.167

3.  VMD: visual molecular dynamics.

Authors:  W Humphrey; A Dalke; K Schulten
Journal:  J Mol Graph       Date:  1996-02

4.  Meprin β and BMP-1 are differentially regulated by CaCl2.

Authors:  Janna Schneppenheim; Franka Scharfenberg; Ralph Lucius; Christoph Becker-Pauly; Philipp Arnold
Journal:  Cell Calcium       Date:  2017-03-19       Impact factor: 6.817

5.  A genetic variation of cathepsin D is a major risk factor for Alzheimer's disease.

Authors:  A Papassotiropoulos; M Bagli; A Kurz; J Kornhuber; H Förstl; W Maier; J Pauls; N Lautenschlager; R Heun
Journal:  Ann Neurol       Date:  2000-03       Impact factor: 10.422

Review 6.  α-Synuclein in Parkinson's disease: causal or bystander?

Authors:  Peter Riederer; Daniela Berg; Nicolas Casadei; Fubo Cheng; Joseph Classen; Christian Dresel; Wolfgang Jost; Rejko Krüger; Thomas Müller; Heinz Reichmann; Olaf Rieß; Alexander Storch; Sabrina Strobel; Thilo van Eimeren; Hans-Ullrich Völker; Jürgen Winkler; Konstanze F Winklhofer; Ullrich Wüllner; Friederike Zunke; Camelia-Maria Monoranu
Journal:  J Neural Transm (Vienna)       Date:  2019-06-25       Impact factor: 3.575

7.  The cathepsin D rs17571 polymorphism: effects on CSF tau concentrations in Alzheimer disease.

Authors:  Matthias Riemenschneider; Kaj Blennow; Stefan Wagenpfeil; Niels Andreasen; Jonathan A Prince; Simon M Laws; Hans Förstl; Alexander Kurz
Journal:  Hum Mutat       Date:  2006-06       Impact factor: 4.878

Review 8.  Lysosomal cathepsins and their regulation in aging and neurodegeneration.

Authors:  Veronika Stoka; Vito Turk; Boris Turk
Journal:  Ageing Res Rev       Date:  2016-04-26       Impact factor: 10.895

9.  Association between cathepsin D polymorphism and Alzheimer's disease in a Chinese Han population.

Authors:  Xiao-Qing Li; Deng Chen; Zhen-Xin Zhang; Qiu-Ming Qu; Jun-Wu Zhang
Journal:  Dement Geriatr Cogn Disord       Date:  2004-06-18       Impact factor: 2.959

Review 10.  Current and Emerging Treatment Strategies for Neuronal Ceroid Lipofuscinoses.

Authors:  Alfried Kohlschütter; Angela Schulz; Udo Bartsch; Stephan Storch
Journal:  CNS Drugs       Date:  2019-04       Impact factor: 5.749

View more
  9 in total

Review 1.  Cathepsin D-Managing the Delicate Balance.

Authors:  Olja Mijanovic; Anastasiia I Petushkova; Ana Brankovic; Boris Turk; Anna B Solovieva; Angelina I Nikitkina; Sergey Bolevich; Peter S Timashev; Alessandro Parodi; Andrey A Zamyatnin
Journal:  Pharmaceutics       Date:  2021-06-05       Impact factor: 6.321

2.  Recombinant pro-CTSD (cathepsin D) enhances SNCA/α-Synuclein degradation in α-Synucleinopathy models.

Authors:  Susy Prieto Huarcaya; Alice Drobny; André R A Marques; Alessandro Di Spiezio; Jan Philipp Dobert; Denise Balta; Christian Werner; Tania Rizo; Lisa Gallwitz; Simon Bub; Iva Stojkovska; Nandkishore R Belur; Jens Fogh; Joseph R Mazzulli; Wei Xiang; Amitkumar Fulzele; Mario Dejung; Markus Sauer; Beate Winner; Stefan Rose-John; Philipp Arnold; Paul Saftig; Friederike Zunke
Journal:  Autophagy       Date:  2022-04-28       Impact factor: 13.391

3.  The role of lysosomes in alpha-synucleinopathies: a focus on glial cells.

Authors:  Denise Balta; Friederike Zunke
Journal:  Neural Regen Res       Date:  2022-07       Impact factor: 5.135

Review 4.  Autophagy in the Neuronal Ceroid Lipofuscinoses (Batten Disease).

Authors:  William D Kim; Morgan L D M Wilson-Smillie; Aruban Thanabalasingam; Stephane Lefrancois; Susan L Cotman; Robert J Huber
Journal:  Front Cell Dev Biol       Date:  2022-02-16

Review 5.  CRISPR and iPSCs: Recent Developments and Future Perspectives in Neurodegenerative Disease Modelling, Research, and Therapeutics.

Authors:  Tirthankar Sen; Rajkumar P Thummer
Journal:  Neurotox Res       Date:  2022-08-31       Impact factor: 3.978

Review 6.  Proteolytic α-Synuclein Cleavage in Health and Disease.

Authors:  Alexandra Bluhm; Sarah Schrempel; Stephan von Hörsten; Anja Schulze; Steffen Roßner
Journal:  Int J Mol Sci       Date:  2021-05-21       Impact factor: 5.923

7.  A Comparison of Various Chips Used for the Manufacture of Biosensors Applied in Non-Fluidic Array SPRi, Based on the Example of Determination of Cathepsin D.

Authors:  Pawel Falkowski; Piotr Mrozek; Piotr Miluski; Zenon Lukaszewski; Ewa Gorodkiewicz
Journal:  Biosensors (Basel)       Date:  2021-12-31

Review 8.  Lysosomal peptidases-intriguing roles in cancer progression and neurodegeneration.

Authors:  Janko Kos; Ana Mitrović; Milica Perišić Nanut; Anja Pišlar
Journal:  FEBS Open Bio       Date:  2022-02-03       Impact factor: 2.693

9.  The c.863A>G (p.Glu288Gly) variant of the CTSD gene is not associated with CLN10 disease.

Authors:  Juan Yang; Xiaoting Ding; Shasha Meng; Jinhua Cai; Weihui Zhou
Journal:  Mol Genet Genomic Med       Date:  2021-07-31       Impact factor: 2.183

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.